Giardia duodenalis mouse model for the development of novel antigiardial agents

Rebecca J Abraham; Mark O'Dea; Bertha Rusdi; Stephen W Page; Ryan O'Handley; Sam Abraham

doi:10.1016/j.mimet.2017.11.025

Giardia duodenalis mouse model for the development of novel antigiardial agents

J Microbiol Methods. 2018 Feb:145:7-9. doi: 10.1016/j.mimet.2017.11.025. Epub 2017 Dec 1.

Authors

Rebecca J Abraham¹, Mark O'Dea², Bertha Rusdi², Stephen W Page³, Ryan O'Handley⁴, Sam Abraham²

Affiliations

¹ Murdoch University, 90 South Street, Murdoch, Western Australia 6150, Australia; The University of Adelaide School of Animal and Veterinary Science, Mudla Wirra Rd, Roseworthy, South Australia 5352, Australia. Electronic address: r.abraham@murdoch.edu.au.
² Murdoch University, 90 South Street, Murdoch, Western Australia 6150, Australia.
³ Neoculi Pty. Ltd., Burwood, Victoria 3125, Australia.
⁴ The University of Adelaide School of Animal and Veterinary Science, Mudla Wirra Rd, Roseworthy, South Australia 5352, Australia.

PMID: 29198594
DOI: 10.1016/j.mimet.2017.11.025

Abstract

This study describes a neonatal mouse model of Giardia infection for development of novel antigiardials. Mice were infected with the axenically cultured Assemblage A BAH2c2 strain, with 10⁵ trophozoites per animal recovered. This model proved to be robust and consistent for use in preliminary drug efficacy trials and drug development.

Keywords: Drug discovery; Giardiasis; Infection model.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Animals
Animals, Suckling
Antiprotozoal Agents / pharmacology*
Disease Models, Animal*
Drug Evaluation, Preclinical*
Feces / parasitology
Giardia lamblia / drug effects*
Giardiasis / drug therapy*
Giardiasis / parasitology
Humans
Intestine, Small / parasitology
Mice*

Substances

Antiprotozoal Agents